Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $18.88 Consensus Target Price from Brokerages

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) has been assigned a consensus rating of “Moderate Buy” from the nine research firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $18.8750.

LXEO has been the topic of a number of recent research reports. Chardan Capital reaffirmed a “buy” rating and set a $17.00 price target on shares of Lexeo Therapeutics in a research report on Tuesday, January 13th. Weiss Ratings cut Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. HC Wainwright dropped their price objective on shares of Lexeo Therapeutics from $13.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, January 13th. Finally, Wall Street Zen lowered shares of Lexeo Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 2nd.

Insider Activity at Lexeo Therapeutics

In related news, CEO Richard Nolan Townsend sold 55,000 shares of the firm’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $5.69, for a total value of $312,950.00. Following the completion of the transaction, the chief executive officer directly owned 340,106 shares of the company’s stock, valued at approximately $1,935,203.14. This trade represents a 13.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 68,189 shares of company stock worth $397,156. Corporate insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Lexeo Therapeutics

Several institutional investors have recently made changes to their positions in LXEO. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Lexeo Therapeutics by 69.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock valued at $35,000 after purchasing an additional 1,459 shares in the last quarter. Vanguard Personalized Indexing Management LLC lifted its holdings in Lexeo Therapeutics by 10.6% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 16,595 shares of the company’s stock worth $110,000 after purchasing an additional 1,595 shares in the last quarter. Bank of America Corp DE lifted its holdings in Lexeo Therapeutics by 6.1% during the 3rd quarter. Bank of America Corp DE now owns 28,279 shares of the company’s stock worth $188,000 after purchasing an additional 1,626 shares in the last quarter. California State Teachers Retirement System boosted its stake in Lexeo Therapeutics by 123.7% in the 4th quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock worth $39,000 after purchasing an additional 2,148 shares during the period. Finally, Intech Investment Management LLC boosted its stake in Lexeo Therapeutics by 19.5% in the 4th quarter. Intech Investment Management LLC now owns 14,188 shares of the company’s stock worth $141,000 after purchasing an additional 2,317 shares during the period. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Stock Up 4.5%

Shares of LXEO stock opened at $6.23 on Friday. The firm has a market cap of $489.18 million, a P/E ratio of -2.84 and a beta of 1.52. The company has a 50 day moving average of $6.28 and a 200-day moving average of $7.85. Lexeo Therapeutics has a 12-month low of $2.43 and a 12-month high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings data on Monday, March 30th. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.05. As a group, equities analysts expect that Lexeo Therapeutics will post -1.27 EPS for the current year.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.